Exact Mass: 307.1874
Exact Mass Matches: 307.1874
Found 111 metabolites which its exact mass value is equals to given mass value 307.1874,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Benzatropine
Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinsons disease. It may also be used to treat extrapyramidal reactions, such as dystonia and Parkinsonism, caused by antipsychotics (e.g. phenothiazines). Symptoms of Parkinsons disease and extrapyramidal reactions arise from decreases in dopaminergic activity which creates an imbalance between dopaminergic and cholinergic activity. Anticholinergic therapy is thought to aid in restoring this balance leading to relief of symptoms. In addition to its anticholinergic effects, benztropine also inhibits the reuptake of dopamine at nerve terminals via the dopamine transporter. Benzotropine also produces antagonistic effects at the histamine H1 receptor. N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AC - Ethers of tropine or tropine derivatives D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018765 - Dopamine Uptake Inhibitors D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
m344
D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors
Ibopamine
Ibopamine is a sympathomimetic used in ophthalmology. It induces mydriasis. It also has been investigated for use in the treatment of congestive heart failure. C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents S - Sensory organs > S01 - Ophthalmologicals > S01F - Mydriatics and cycloplegics > S01FB - Sympathomimetics excl. antiglaucoma preparations D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
Hydroxyterbinafine
Hydroxyterbinafine is a metabolite of terbinafine. Terbinafine hydrochloride is a synthetic allylamine antifungal from Novartis. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. (Wikipedia)
4-Phenylbutanoylcarnitine
4-Phenylbutanoylcarnitine is an acylcarnitine. More specifically, it is an 4-phenylbutanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Phenylbutanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Phenylbutanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Buflomedil
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
Buflomedil
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor CONFIDENCE standard compound; EAWAG_UCHEM_ID 3068
2-(3,5-Dimethyl-2-oxo-4,6-octadienyl)tetrahydro-6-oxo-2H-pyran-4-acetamide
1-(2-hydroxy-3-methyl)-butyl-hydrocotarnine
5-Hepten-3-yn-1-ol, 2,2-dimethyl-7-[methyl(1-naphthalenylmethyl)amino]-, (E)-
Ibopamine
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents S - Sensory organs > S01 - Ophthalmologicals > S01F - Mydriatics and cycloplegics > S01FB - Sympathomimetics excl. antiglaucoma preparations D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
ETHYL 4-(BENZYL(2-ETHOXY-2-OXOETHYL)AMINO)BUTANOATE
METHYL 2-N-BOC-2-AMINOMETHYL)-3-M-TOLYL-PROPIONATE
ETHYL 4-((1-METHYLPIPERIDIN-4-YL)METHOXY)-3-METHOXYBENZOATE
4-[6-(4-propan-2-ylpiperazin-1-yl)pyridazin-3-yl]benzonitrile
methyl 2-[(4-methylphenyl)methyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
2-(1,1-Diethoxymethyl)pyridine-3-boronic acid pinacol ester
9-(6-methoxynaphthalen-2-yl)-3-azaspiro[5.5]undec-9-ene
1H-Pyrrolo[2,3-b]pyridin-5-amine, 4-fluoro-1-[tris(1-methylethyl)silyl]-
2-(2-(BENZYLOXY)-5-(TERT-BUTYL)PHENYL)-2-METHYLPROPANENITRILE
b-Alanine,N-(3-methoxy-2-methyl-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester
4-[2-(4-propan-2-ylpiperazin-1-yl)pyrimidin-5-yl]benzonitrile
2-N-BOC-2-METHYLAMINOMETHYL-3-M-TOLYL-PROPIONIC ACID
2-N-BOC-2-METHYLAMINOMETHYL-3-P-TOLYL-PROPIONIC ACID
b-Alanine,N-(3-ethoxy-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester
5-(1-Piperidinylmethyl)thiophene-2-boronic acid pinacol ester
tert-butyl 4-(5-amino-2-methoxyphenyl)piperazine-1-carboxylate
3-((TERT-BUTOXYCARBONYL)AMINO)-3-(4-ISOPROPYLPHENYL)PROPANOIC ACID
1-Boc-4-(((3-Aminopyridin-2-yl)oxy)methyl)piperidine
3,5-Dimethyl-2,6-bis(4-methylphenyl)piperidin-4-one
N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine
L-Alanyl-N-[(1s,2r)-1-Benzyl-2-Hydroxypropyl]-L-Alaninamide
1-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-methylbutan-2-ol
3-Methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid
(2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide
(2R,3R)-8-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-10-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-10-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-8-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-8-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-8-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-10-amino-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-10-amino-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(E)-N-[3-(4-aminobutylamino)propyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide
Cogentin
N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AC - Ethers of tropine or tropine derivatives D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018765 - Dopamine Uptake Inhibitors D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane
N-dodecanoyltaurine
A fatty acid-taurine conjugate derived from dodecanoic acid.
2-{[(6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl)(hydroxy)methylidene]amino}-3-methylbutanoic acid
(2z,4e)-n-(2-{[(3s)-2-hydroxy-3,4,5,6-tetrahydropyridin-3-yl]-c-hydroxycarbonimidoyl}ethyl)-6-methylhepta-2,4-dienimidic acid
6-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one
(5e,8r,9e)-3-(2-methoxy-2-oxoethyl)-8,10-dimethyl-7-oxododeca-5,9,11-trienimidic acid
(2s)-2-({[(3ar,6r,7ar)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid
(1's,2'r,3's,4s,6'r)-3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione
6-hydroxydendroxine
{"Ingredient_id": "HBIN012430","Ingredient_name": "6-hydroxydendroxine","Alias": "NA","Ingredient_formula": "C17H25NO4","Ingredient_Smile": "CC(C)C1C2C(=O)OC1C34C5(C2(CCC5CN3CCO4)O)C","Ingredient_weight": "307.389","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9983","TCMSP_id": "NA","TCM_ID_id": "7545","PubChem_id": "NA","DrugBank_id": "NA"}
